InvestorsHub Logo
Followers 20
Posts 405
Boards Moderated 0
Alias Born 11/21/2013

Re: None

Wednesday, 03/01/2017 11:18:15 AM

Wednesday, March 01, 2017 11:18:15 AM

Post# of 474273
Another failed Phase III for AD....do we have the goods with AVXL? I think we may!

"A phase 3 trial of Accera’s Alzheimer’s disease candidate has missed its primary endpoint. The trial aimed to show Accera’s brain metabolism-focused approach to improving outcomes in Alzheimer’s could succeed where beta-amyloid drugs have failed, but instead ended up becoming yet another late-phase failure."
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News